ApcinteX Ltd.
- Country
- π¬π§United Kingdom
- Ownership
- Subsidiary
- Established
- 2014-06-16
- Employees
- 1
- Market Cap
- -
- Website
- http://www.apcintex.com
The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial
- Conditions
- Hemophilia aHemophilia BHemophilia a with InhibitorHemophilia B with Inhibitor
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- ApcinteX Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT06568302
- Locations
- π¬πͺ
ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia
π²π©Institute of Oncology, ARENSIA Exploratory Medicine, Chisinau, Moldova, Republic of
The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- ApcinteX Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT05789524
- Locations
- πͺπΈ
Hospital Universitario Miguel Servet, Zaragoza, Spain
πΊπΈUniversity of Colorado School of Medicine, Aurora, Colorado, United States
πΊπΈUniversity of South Florida, Tampa, Florida, United States
A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- ApcinteX Ltd
- Target Recruit Count
- 3
- Registration Number
- NCT05789537
- Locations
- π«π·
Hospices Civils de Lyon (HCL) - Hopital Femme-Mere-Enfant (HFME), Lyon, France
π«π·Hopital Necker - Enfants Malades, Paris, France
π©πͺUniversity Hospital Frankfurt M, Frankfurt, Germany
Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)
- Conditions
- Hemophilia aHemophilia B
- Interventions
- Other: No Intervention
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- ApcinteX Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT05605678
- Locations
- πΊπΈ
University of Michigan, Ann Arbor, Michigan, United States
πΊπΈEast Carolina univeristy, Greenville, South Carolina, United States
π¦π²Centre of Haematology named after prof. R. O. Yeolian, Yerevan, Armenia
The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- ApcinteX Ltd
- Target Recruit Count
- 39
- Registration Number
- NCT04073498
- Locations
- π²π©
Arensia Clinical Research Unit, Chisinau, Moldova, Republic of
π¬π§Simbec Research Ltd, Merthyr Tydfil, Cardiff, United Kingdom